RxDoctor Payments Data

Mark Bilella, MD

Internal Medicine · Tampa, FLNPI 1447200803

Payments from drug & device makers

$11,309in general payments, 2019–2025

Across 614 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Boehringer Ingelheim$789
  • Lilly USA, LLC$780
  • Gilead$654
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$11,308100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,309 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$27,930
Medicare patients
83
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$26,266
JardianceEmpagliflozin12$15,125
Atorvastatin Calcium109$1,094
Pregabalin21$733
Duloxetine Hcl17$681
Omeprazole43$523
Losartan Potassium77$474
Levothyroxine Sodium67$471
Simvastatin49$395
Butalbital-Aspirin-CaffeineButalbital/Aspirin/Caffeine12$378
Chlorthalidone28$374
Zolpidem Tartrate36$367
Pantoprazole Sodium22$357
Fluticasone Propionate19$350
Lisinopril47$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,645$26,26629 claims
Boehringer IngelheimJardiance$789$15,12512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →